Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Zentalis Pharmaceuticals Llc stock

Learn how to easily invest in Zentalis Pharmaceuticals Llc stock.

Zentalis Pharmaceuticals Llc is a biotechnology business based in the US. Zentalis Pharmaceuticals Llc shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. Zentalis Pharmaceuticals Llc employs 177 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Zentalis Pharmaceuticals Llc

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZNTL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Zentalis Pharmaceuticals Llc stock price (NASDAQ: ZNTL)

Use our graph to track the performance of ZNTL stocks over time.

Zentalis Pharmaceuticals Llc shares at a glance

Information last updated 2022-06-24.
Latest market close$26.94
52-week range$17.33 - $87.19
50-day moving average $23.86
200-day moving average $54.73
Wall St. target price$82.40
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.82

Buy Zentalis Pharmaceuticals Llc shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zentalis Pharmaceuticals Llc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zentalis Pharmaceuticals Llc price performance over time

Historical closes compared with the close of $26.94 from 2022-06-28

1 week (2022-06-22) 7.25%
1 month (2022-05-27) 8.85%
3 months (2022-03-30) -40.90%
6 months (2021-12-30) -67.42%
1 year (2021-06-30) -49.36%
2 years (2020-06-30) -43.90%
3 years (2019-06-26) N/A
5 years (2017-06-26) N/A

Zentalis Pharmaceuticals Llc financials

Gross profit TTM $0
Return on assets TTM -36.66%
Return on equity TTM -57.5%
Profit margin 0%
Book value $6.92
Market capitalisation $1.6 billion

TTM: trailing 12 months

Zentalis Pharmaceuticals Llc share dividends

We're not expecting Zentalis Pharmaceuticals Llc to pay a dividend over the next 12 months.

Zentalis Pharmaceuticals Llc share price volatility

Over the last 12 months, Zentalis Pharmaceuticals Llc's shares have ranged in value from as little as $17.33 up to $87.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zentalis Pharmaceuticals Llc's is 2.7474. This would suggest that Zentalis Pharmaceuticals Llc's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Zentalis Pharmaceuticals Llc overview

Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Zentalis Pharmaceuticals Llc is owned by insiders or institutions?
Currently 7.492% of Zentalis Pharmaceuticals Llc shares are held by insiders and 90.928% by institutions.
How many people work for Zentalis Pharmaceuticals Llc?
Latest data suggests 177 work at Zentalis Pharmaceuticals Llc.
When does the fiscal year end for Zentalis Pharmaceuticals Llc?
Zentalis Pharmaceuticals Llc's fiscal year ends in December.
Where is Zentalis Pharmaceuticals Llc based?
Zentalis Pharmaceuticals Llc's address is: 1359 Broadway, New York, NY, United States, 10018
What is Zentalis Pharmaceuticals Llc's ISIN number?
Zentalis Pharmaceuticals Llc's international securities identification number is: US98943L1070
What is Zentalis Pharmaceuticals Llc's CUSIP number?
Zentalis Pharmaceuticals Llc's Committee on Uniform Securities Identification Procedures number is: 98943L107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site